NCT00935480 - IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

November 12, 2010

Study Completion Date

August 8, 2014

Conditions

HIV Infections

Interventions

DRUG

Isentress®

P.O, 1 tablet containing 400 mg every 12 hours

DRUG

Celsentri®

p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)

Trial Locations (2)

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Service d'infectiologie, Toulon

Centre Hospitalier Intercommunal de Toulon La Seyne sur mer, Toulon